Brief: Medicenna Presents New Preclinical Results For Its Il-2 Superkine Platform, Mdna109
20/06/2019 13:07
June 20 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS NEW PRECLINICAL RESULTS FOR ITS IL-2
SUPERKINE PLATFORM, MDNA109
* MEDICENNA - MDNA109 PROVIDES DURABLE TUMOR CONTROL AND
STRONG
MEMORY RESPONSE WITHOUT FURTHER TREATMENT WHEN COMBINED WITH
CHECKPOINT INHIBITORS
Source text for Eikon: ID:nCNW9N396a
Further company coverage: MDNA.TO
((Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results